Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritis.
Geography, School of Social Sciences, University of Dundee, Dundee, DD1 4HN, UK j.m.mendel@dundee.ac.uk.
Jonathan
J
Mendel
Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK.
Ben
B
Goldacre
Peninsula Medical School, University of Exeter, Exeter, UK.
Edzard
E
Ernst
Discipline of Medicine, University of Adelaide, Australia.
Samuel
S
Whittle
D022126:Access to Information / Q000941:ethics; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000379:methods*; D004282:Documentation / Q000941:ethics / Q000379:methods; D004345:Drug Industry / Q000941:ethics / Q000379:methods; D017041:Ethics Committees; D006705:Homeopathy / Q000941:ethics / Q000379:methods; D006801:Humans; D007258:Informed Consent / Q000941:ethics; D012308:Risk Management / Q000941:ethics / Q000379:methods; D006113:United Kingdom
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C533411:ocrelizumab